Seeking Alpha

Vical (VICL) says the addition of its Vaxfectin adjuvant to Baxter's (BAX) influenza vaccines...

Vical (VICL) says the addition of its Vaxfectin adjuvant to Baxter's (BAX) influenza vaccines "substantially increases both antibody and T-cell responses." VICL's VP of vaccine research says seasonal influenza vaccines sometimes underperform in elderly patients — "a good adjuvant could" help, he adds. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs